Áö³ª½Ãµå°ÇÁ¶½Ã·´800mg/5mL (150mL) JINACID SYR.[Acyclovir]
Àü¹®ÀǾàǰ | »èÁ¦
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
»ç¿ëÇÒ ¶§ ³ì¿©¾²´Â ¿¬ºÐ È«»ö °¡·ç
Á¦Á¶È¸»ç
Áø¾çÁ¦¾à(ÁÖ)
ÆÇ¸Åȸ»ç
Áø¾çÁ¦¾à(ÁÖ)
Çã°¡Á¤º¸
ÃëÇÏ
(2023.04.01)
BIT ¾àÈ¿ºÐ·ù
Ç×¹ÙÀÌ·¯½ºÁ¦ (Antiviral Agents)
º¹ÁöºÎºÐ·ù
629[±âŸÀÇ ÈÇпä¹ýÁ¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
650301151\0 ¿ø/150(1)mL/º´(2018.03.01) (ÇöÀç¾à°¡) \373 ¿ø/150(1)mL/º´(2016.01.01)(º¯°æÀü¾à°¡)
ATCÄÚµå
Aciclovir / J05AB01
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
µþ±âÄÚÅæ ,
¹Ì°áÁ¤¼¿·ê·Î¿ì½º ,
¹é´ç ,
½ÃÆ®¸£»ê¼öȹ° ,
¿°È³ªÆ®·ý ,
ÀÜź°Ë ,
Àû»ö3È£ ,
Æú¸®¼Ò¸£º£ÀÌÆ®80 ,
È÷ÇÁ·Î¸á·Î¿À½º2910 ,
D-¸¸´ÏÅç
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
650301151
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/150(1)mL/º´(2018.03.01) (ÇöÀç¾à°¡)
\373 ¿ø/150(1)mL/º´(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
»ç¿ëÇÒ ¶§ ³ì¿©¾²´Â ¿¬ºÐ È«»ö °¡·ç [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
20±×¶÷(Çöʾ×À¸·Î 30¹Ð¸®¸®ÅÍ), 320±×¶÷(Çöʾ×À¸·Î 480¹Ð¸®¸®ÅÍ)
ÁÖ¼ººÐÄÚµå
102944ASY
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
1. Ãʹ߼º ¹× Àç¹ß¼º »ý½Ä±âÆ÷ÁøÀ» Æ÷ÇÔÇÑ ÇǺΠ¹× Á¡¸·Á¶Á÷ÀÇ ´Ü¼øÆ÷Áø ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ Ä¡·á ¹× ¿¹¹æ
2. ´ë»óÆ÷Áø ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ Ä¡·á, ƯÈ÷ ±Þ¼º½ÃÀÇ ÅëÁõ¿¡ È¿°ú°¡ ÀÖ´Ù. ¹Ý¸é Æ÷ÁøÈÄ ½Å°æÅë¿¡ ´ëÇÑ È¿°ú´Â ¾ÆÁ÷ Áõ¸íµÇÁö ¾Ê¾Ò´Ù.
3. 2¼¼ ÀÌ»ó ¼Ò¾ÆÀÇ ¼öµÎ Ä¡·á
Çã°¡»çÇ× Ãʰú½Ã ÀÎÁ¤±âÁØ
[Á¶È¸]
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û ¼ºÀÎ
1. ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ Ä¡·á
1) ¾Æ½ÃŬ·Î¹ö·Î¼ 1ÀÏ 5ȸ, 1ȸ 200 mg¾¿ 4½Ã°£ °£°ÝÀ¸·Î 5Àϰ£ Åõ¿©Çϸç, ÁßÁõ Ãʹ߼º °¨¿°ÁõÀÎ °æ¿ì, Ä¡·á¸¦ ¿¬ÀåÇÒ ¼ö ÀÖ´Ù.
2) ÁßÁõ ¸é¿ª±â´ÉÀúÇÏ È¯ÀÚ(°ñ¼öÀ̽ÄÈÄ µî)¶Ç´Â ¼ÒȰü Èí¼öÀå¾Ö ȯÀÚ´Â 1ȸ Åõ¿©·®À» 400 mg±îÁö Áõ·®Çϰųª Á¤¸ÆÁÖ»ç·Î Åõ¿©°æ·Î¸¦ ¹Ù²Ü ¼ö ÀÖ´Ù.
3) °¨¿° ÈÄ ÃÖ´ëÇÑ »¡¸® Åõ¿©ÇÏ´Â °ÍÀÌ ÁÁÀ¸¸ç, Àç¹ß¼ºÀÎ °æ¿ì ÀüÁ¶Áõ»óÀ̳ª º´º¯ÀÌ Ã³À½ ³ªÅ¸³¯ ¶§ Åõ¿©ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
2. ¸é¿ª±â´ÉÀÌ Á¤»óÀΠȯÀÚÀÇ ´Ü¼øÆ÷Áø °¨¿°ÁõÀÇ ¿¹¹æ
1) ÀÌ ¾àÀ¸·Î¼ 1ÀÏ 4ȸ, 1ȸ 200 mgÀ» ¾à 6½Ã°£ °£°ÝÀ¸·Î Åõ¿©ÇÑ´Ù. ¶Ç´Â 1ÀÏ 2ȸ, 1ȸ 400 mg¾¿ 12½Ã°£ °£°ÝÀ¸·Î Åõ¿©ÇÒ ¼öµµ ÀÖ´Ù.
2) ±× ÈÄ 1ȸ 200 mg¾¿ 1ÀÏ 2¢¦3ȸ·Î °¨·®ÇÏ¿© ±× À¯È¿¼ºÀ» È®ÀÎÇÑ ÈÄ °¨·®ÇÒ ¼öµµ ÀÖ´Ù.
3) ÁúȯÀÇ ÀÚ¿¬ÀûÀÎ º¯È°úÁ¤À» È®ÀÎÇϱâ À§Çؼ´Â, Àå±âÄ¡·á ȯÀÚ´Â ¸Å 6¢¦12°³¿ù¸¶´Ù ÁÖ±âÀûÀ¸·Î Ä¡·á¸¦ Áß´ÜÇÏ¿© È®ÀÎÇØ º¸¾Æ¾ß ÇÑ´Ù.
3. ¸é¿ª±â´ÉÀÌ ÀúÇÏµÈ È¯ÀÚÀÇ ´Ü¼øÆ÷Áø °¨¿°ÁõÀÇ ¿¹¹æ
1) ÀÌ ¾àÀ¸·Î¼ 1ÀÏ 4ȸ, 1ȸ 200 mg¾¿ ¾à 6½Ã°£ °£°ÝÀ¸·Î Åõ¿©ÇÑ´Ù.
2) ÁßÁõ ¸é¿ª±â´ÉÀúÇÏ È¯ÀÚ(°ñ¼öÀÌ½Ä ÈÄ µî) ¶Ç´Â ¼Òȱâ°ü Èí¼öÀå¾Ö ȯÀÚ¿¡´Â 1ȸ Åõ¿©·®À» 400 mg±îÁö Áõ·®Çϰųª Á¤¸ÆÁÖ»ç·Î Åõ¿©°æ·Î¸¦ ¹Ù²Ü ¼ö ÀÖ´Ù.
3) °¨¿°À§Çè ±â°£ µ¿¾È Åõ¿©ÇÑ´Ù.
4. ´ë»óÆ÷Áø °¨¿°ÁõÀÇ Ä¡·á
1) ÀÌ ¾àÀ¸·Î¼ 1ÀÏ 5ȸ, 1ȸ 800 mg¾¿ Ãëħ½Ã°£À» Á¦¿ÜÇÏ°í ¾à 4½Ã°£ °£°ÝÀ¸·Î Åõ¿©Çϸç, ÃÑ 7Àϰ£ Åõ¿©ÇÑ´Ù.
2) ÁßÁõ ¸é¿ª±â´ÉÀúÇÏ È¯ÀÚ ¶Ç´Â ¼Òȱâ°ü Èí¼öÀå¾Ö ȯÀÚ´Â Á¤¸ÆÁÖ»ç·Î Åõ¿©ÇÏ´Â °ÍÀ» °í·ÁÇØ¾ß ÇÑ´Ù.
3) °¨¿° ÈÄ ÃÖ´ëÇÑ »¡¸® Åõ¿©ÇÏ´Â °ÍÀÌ ÁÁÀ¸¸ç, »¡¸® Ä¡·áÇÒ¼ö·Ï ´õ ÁÁÀº È¿°ú°¡ ³ªÅ¸³´Ù.
¡Û ¼Ò¾Æ
1. ´Ü¼øÆ÷Áø °¨¿°ÁõÀÇ Ä¡·á ¹× ¸é¿ª±â´ÉÀÌ ÀúÇÏµÈ È¯ÀÚÀÇ ´Ü¼øÆ÷Áø °¨¿°ÁõÀÇ ¿¹¹æ
1) 2¼¼ ÀÌ»ó : ¼ºÀο¡ ÁØÇÔ.
2) 2¼¼ ¹Ì¸¸ : ¼ºÀο뷮ÀÇ 1/2À» Åõ¿©ÇÔ.
3) ¸é¿ª±â´ÉÁ¤»ó ȯÀÚÀÇ ´Ü¼øÆ÷Áø ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ ¿¹¹æ¿¡ ´ëÇÑ È®½ÇÇÑ ÀÚ·á´Â ¾ÆÁ÷ ¾ø´Ù.
2. 2¼¼ ÀÌ»ó ¼Ò¾ÆÀÇ ¼öµÎÄ¡·á : ÀÌ ¾àÀ¸·Î¼ 1ȸ üÁß kg´ç 20 mg(1ȸ ÃÖ´ë 800 mg)¾¿ 1ÀÏ 4ȸ, 5Àϰ£ Åõ¿©ÇÑ´Ù.
Ä¡·á´Â ¼öµÎ¹ßÁøÀÌ ³ªÅ¸³ ÈÄ ºü¸¦¼ö·Ï ÁÁÀ¸¸ç °¡±ÞÀû ¹ßÁø ÈÄ 24½Ã°£ À̳»¿¡ Åõ¿©ÇÑ´Ù.
¡Û ½ÅÀå¾Ö ȯÀÚ
½ÅÀå¾Ö ȯÀÚ´Â Á¤½Å½Å°æ°è ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î Åõ¿©°£°ÝÀ» ¿¬ÀåÇϰųª °¨·®ÇÏ´Â µî ÁÖÀÇÇØ¾ß ÇÑ´Ù.
1. ´Ü¼øÆ÷Áø °¨¿°ÁõÀÇ Ä¡·á
°æ±¸ ¿ë·®Àº Á¤¸ÆÁÖ»ç·Î ÀÎÇÑ ÃàÀû·®º¸´Ù ³ôÁö ¾Ê´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª ÁßÁõ ½ÅÀå¾Ö ȯÀÚ(Å©·¹¾ÆÆ¼´Ñ û¼ÒÀ²ÀÌ ºÐ´ç 10 mL ¹Ì¸¸)´Â ÀÌ ¾àÀ» 12½Ã°£¸¶´Ù 200 mg¾¿ Åõ¿©ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
2. ´ë»óÆ÷Áø ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ Ä¡·á
½ÉÇÑ ½ÅÀå¾Ö ȯÀÚ(Å©·¹¾ÆÆ¼´Ñ û¼ÒÀ²ÀÌ ºÐ´ç 10 mL ¹Ì¸¸)´Â ÀÌ ¾àÀ¸·Î¼ 1ȸ 800 mg 1ÀÏ 3¢¦4ȸ, ¾à 6¢¦8½Ã°£ °£°ÝÀ¸·Î °¨·® Åõ¿©ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
±Ý±â
ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ ¹× ¹ß¶ó½ÃŬ·Î¹ö¿¡ ´ëÇÑ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
½ÅÁßÅõ¿©
1) ½ÅÀå¾Ö ȯÀÚ(Á¤½Å½Å°æ°èÀÇ ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³ª±â ½±´Ù.)
2) °£Àå¾Ö ȯÀÚ(°£±â´ÉÀÌ ´õ ¾ÇȵDZ⠽±´Ù.)
3) ¿µ․À¯․¼Ò¾Æ
4) °í·ÉÀÚ
ÀÌ»ó¹ÝÀÀ
1) ¼ï : µå¹°°Ô ¾Æ³ªÇʶô½Ã ¼ï, ¾Æ³ªÇʶô½Ã¾ç ¹ÝÀÀÀÌ ³ªÅ¸³ª´Â °æ¿ì°¡ ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí, Ç÷¾Ð°ÇÏ, È£Èí°ï¶õ, ÈäºÎ¾Ð¹Ú°¨ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù
2) °ú¹Î¹ÝÀÀ : ±¤°ú¹Î¹ÝÀÀ, °íÁ¤¾àÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¶§¶§·Î ¹ßÁø, ¹ß¿, ¼öÆ÷, µÎµå·¯±â¾ç È«¹Ý, µÎµå·¯±â°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ÇǺΠ: Å»¸ðÁõ, ´ÙÇüÈ«¹Ý, ÇǺÎÁ¡¸·¾ÈÁõÈıº(½ºÆ¼ºì½º-Á¸½¼ÁõÈıº), Áßµ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ(¸®¿¤ÁõÈıº)°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) Á¤½Å½Å°æ°è : ÀǽÄÀå¾Ö, ¹æÇâ°¨°¢Àå¾Ö, ÁýÁß·ÂÀå¾Ö, °ø°ÝÀûÀÎ Çൿ, ÀÌÀÎÁõ(ìÆìÑñø), ÃÊÁ¶, Á¶È¿îµ¿ºÒ´É, È¥¼ö, Âø¶õ, ¼¶¸Á, ¸»´õµë, ³úº´Áõ, ȯ°¢, Á¤½Åº´, °æ·Ã, Á¹À½, ¶³¸², ÈïºÐ, °Ç¸Á, ºÒ¸é, ºÒ¾È, È¥À㸻, À̻󰨰¢, ¿îµ¿½ÇÁ¶, º¸ÇàºÒ´É, ºÒ¼öÀÇ ¿îµ¿, ¾È±¸ÁøÅÁ, µå¹°°Ô ¶³¸², Á¹À½, ¾îÁö·¯¿òÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ»óÀº °í·ÉÀÚ³ª ½ÅÀå¾ÖÀÚ¿¡¼ ´õ ÀÚÁÖ ³ªÅ¸³´Ù.
5) ½ÅÀå : ½ÅºÎÀü, °áÁ¤´¢, ¶§¶§·Î BUN, Ç÷ûũ·¹¾ÆÆ¼´Ñ »ó½Â, µå¹°°Ô Ç÷´¢, ´Ü¹é´¢, ¿äÁß ÀûÇ÷±¸¿øÁÖ, ³ó´¢°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) Ç÷¾× ¹× ¸²ÇÁ°è : ¹éÇ÷±¸ÆÄ±«Ç÷°ü¿°, ¸²ÇÁÀýº´Áõ, ÃâÇ÷, ÀÚ¹Ý, ¶§¶§·Î ºóÇ÷, ¹éÇ÷±¸ °¨¼Ò ¶Ç´Â Áõ°¡, È£»ê±¸ Áõ°¡, µå¹°°Ô ¸²ÇÁ±¸ Áõ°¡, Ç÷¼ÒÆÇ Áõ°¡, °ú¸³±¸ °¨¼Ò, Ç÷¼ÒÆÇ °¨¼Ò, È£¿°±â±¸ Áõ°¡°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) °£Àå : °£¿°, °£Àå¾Ö, Ȳ´Þ, ¶§¶§·Î °£±â´É °Ë»çÀÇ ÀÌ»ó(AST/ALT, LDH, ALP, ÃÑ ºô¸®·çºó »ó½Â), °£ºñ´ë°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ¼Òȱâ°è : À§¿°, ¸ñ¸¶¸§, º¯ºñ, ±Þ¼ºÃéÀå¿°, ¶§¶§·Î ¼³»ç, ¹«¸¥º¯, »óº¹ºÎÅë, À§Åë, º¹Åë, ±¸¿ª, ±¸Åä, µå¹°°Ô ¼ÒȺҷ®, ½Ä¿åºÎÁø, Çô¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
9) Àü½Å : ¹ß¿, ¸»´ÜºÎÁ¾, ½Ç½Å, â¹é, ±Ù·ÂÀúÇÏ, ¹«·Â°¨, ¶§¶§·Î Àü½Å±Çۨ, µÎÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
10) ±Ù°ñ°Ý°è : °üÀýÅë, ±ÙÀ°ÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ¼øÈ¯±â°è : ºÎÁ¤¸Æ, °¡½¿ÅëÁõ, Ç÷¾Ð»ó½Â, Ç÷¾ÐÀúÇÏ, ºó¸Æ, µå¹°°Ô ½É°èÇ×ÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
12) ºñ´¢±â°è : ¿äÆó»ö, µå¹°°Ô ¹è´¢°ï¶õÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
13) ±âŸ : ¿ä´ç, Æó·Å, Àεο°, È£Èí°ï¶õ, Èä¼ö, ÅëÁõ, ³Ã», °á¸·¿°, ½Ã°¢ÀÌ»ó, ¹Ì°¢Àå¾Ö, Å»¸ð, ¹ßÇÑ, Àú³ªÆ®·ýÇ÷Áõ, Ç÷û´Ü¹éÀúÇÏ, ¶§¶§·Î ÃÑÄÝ·¹½ºÅ×·ÑÄ¡, Æ®¸®±Û¸®¼¼¸®µåÄ¡, Ç÷ûĮ·ýÄ¡ÀÇ »ó½Â, µå¹°°Ô Ç÷û¾ËºÎ¹ÎÄ¡ ÀúÇϰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
»óÈ£ÀÛ¿ë
1) ÇÁ·Îº£³×½Ãµå¿Í ÀÌ ¾à ÁÖ»çÁ¦ÀÇ º´¿ë ½Ã ÀÌ ¾àÀÇ Æò±Õ ¹Ý°¨±â¸¦ 18% ¿¬Àå½Ã۰í Ç÷Àå-³óµµ °î¼±ÀÇ ¸éÀû 40% Áõ°¡½Ã۸ç, ¿ä¹èÃâ ¹× ½Åû¼ÒÀ²À» °¨¼Ò½ÃŲ´Ù´Â º¸°í°¡ ÀÖ´Ù.
2) ½ÅÀå±â´É¿¡ ¿µÇâÀ» ÁÖ´Â ¾î¶² ¾à¹°µµ ¾Æ½ÃŬ·Î¹öÀÇ ¾à¹°µ¿·ÂÇп¡ ½ÇÁúÀû ¿µÇâÀ» ÁÙ ¼ö ÀÖ´Ù.
3) ½Ã¸ÞƼµòÀº ÀÌ ¾àÀÇ ¿ä¹èÃâÀ» °¨¼Ò½ÃÄÑ, Ç÷Àå-³óµµ °î¼±ÀÇ ¸éÀûÀ» 27% Áõ°¡½ÃŲ´Ù´Â º¸°í°¡ ÀÖ´Ù.
4) Å׿ÀÇʸ°°ú ÀÌ ¾àÀÇ º´¿ë ½Ã Å׿ÀÇʸ°ÀÇ Áßµ¶Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ¹ÌÄÚÆä³î·¹ÀÌÆ®¸ðÆäÆ¿°ú ÀÌ ¾àÀÇ º´¿ë ½Ã ¹ÌÄÚÆä³î·¹ÀÌÆ®¸ðÆäÆ¿ ´ë»ç¹°ÁúÀÇ ¹èÃâÀ» °¨¼Ò½ÃÄÑ µÎ ¾à ¸ðµÎÀÇ Ç÷Àå-³óµµ °î¼±ÀÇ ¸éÀûÀ» Áõ°¡½ÃŲ´Ù´Â º¸°í°¡ ÀÖ´Ù.
Off-label Usage
[Á¶È¸]
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
650301151
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/150(1)mL/º´(2018.03.01) (Ãֽžడ)
\373 ¿ø/150(1)mL/º´(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
Á¦Ç°¼º»ó
»ç¿ëÇÒ ¶§ ³ì¿©¾²´Â ¿¬ºÐ È«»ö °¡·ç
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
20±×¶÷(Çöʾ×À¸·Î 30¹Ð¸®¸®ÅÍ), 320±×¶÷(Çöʾ×À¸·Î 480¹Ð¸®¸®ÅÍ)
º¸°ü¹æ¹ý
±â¹Ð¿ë±â, ½Ç¿Âº¸°ü
Brandname Á¤º¸
Acyclovir Brand Names/Synonyms
AC2
Aciclovier
Aciclovir
Acycloguanosine
Acyclovir Sodium
Alti-Acyclovir
Avirax
Valtrex
Vipral
Virorax
Wellcome-248u
Zovirax
Zovirax Wellstat Pac
Zovirax Zostab Pac Brand Name Mixtures Zovirax Injection (Zovirax sodium)Chemical IUPAC Name 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Bµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾à¶óº§
À̹ÌÁö
º¹¾à¼³¸í
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù.
*
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù.
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
µ¶¼ºÁ¤º¸
Acyclovir ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Pharmacokinetics
AcyclovirÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö : °æ±¸ : À½½Ä¹°Àº Èí¼ö¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê´Â´Ù.
»ýü³» ÀÌ¿ë·ü : °æ±¸ : 15-30%
ºÐÆ÷ : ³ú, ½ÅÀå, Æó, °£, ºñÀå, ±ÙÀ°, ÀÚ±Ã, Áú, ³úô¼ö¾×À» Æ÷ÇÔÇØ ü³»¿¡ ³Î¸® ºÐÆ÷ÇÑ´Ù.
´Ü¹é°áÇÕ : 30% ÀÌÇÏ
´ë»ç : ¼Ò·®ÀÌ °£´ë»çµÈ´Ù.
¹Ý°¨±â : Terminal phase :
½Å»ý¾Æ : 4½Ã°£
1-12 ¼¼ ¼Ò¾Æ : 2-3 ½Ã°£
¼ºÀÎ : 3½Ã°£
ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ :
°æ±¸ : 1.5-2 ½Ã°£ À̳»
IV : 1½Ã°£ À̳»
¼Ò½Ç : 30-90%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³
Ç÷¾×Åõ¼®À¸·Î 60%±îÁö Á¦°ÅµÇ³ª º¹¸·Åõ¼®ÀÇ È¿°ú´Â ÈξÀ ¶³¾îÁø´Ù (Ãß°¡¿ë·® ÇÊ¿ä).
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields:
The generic name of each chemical
For module A10 (liver enzyme composite module):
Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method)
Number of endpoints at which each compound is marginally active (M)
Number of endpoints at which each compound is active (A)
For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively):
Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method)
Number of ADR reports for each compound, given as <4 or ¡Ã4
Reporting Index value for each compound, except where no shipping units were available (NSU)
Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period.
ACYCLOVIR [GGT Increase] [Composite Activity] (Score) I (Marginal) 0 (Active) 0 [Alkaline Phosphatase Increase] (Activity Score) I (Number of Rpts) ¡Ã4 (Index value) 0.9 [SGOT Increase] (Activity Score) I (Number of Rpts) ¡Ã4 (Index value) 0.9 [SGPT Increase] (Activity Score) I (Number of Rpts) <4 (Index value) 0.1 [LDH Increase] (Activity Score) I (Number of Rpts) <4 (Index value) 0.1 [GGT Increase] (Activity Score) I (Number of Rpts) <4 (Index value) 0
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ